Table of Contents

company-logo

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Swedish Orphan Biovitrum Dividend Announcement

• Swedish Orphan Biovitrum does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Swedish Orphan Biovitrum dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Swedish Orphan Biovitrum Dividend History

Swedish Orphan Biovitrum Dividend Yield

Swedish Orphan Biovitrum current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Swedish Orphan Biovitrum stock? Use our calculator to estimate your expected dividend yield:

Swedish Orphan Biovitrum Financial Ratios

P/E ratio30.53
PEG ratio-0.14
P/B ratio2.89
ROE9.82%
Payout ratio0.00%
Current ratio0.91
Quick ratio0.62
Cash Ratio0.04

Swedish Orphan Biovitrum Dividend FAQ

Does Swedish Orphan Biovitrum stock pay dividends?
Swedish Orphan Biovitrum does not currently pay dividends to its shareholders.
Has Swedish Orphan Biovitrum ever paid a dividend?
No, Swedish Orphan Biovitrum has no a history of paying dividends to its shareholders. Swedish Orphan Biovitrum is not known for its dividend payments.
Why doesn't Swedish Orphan Biovitrum pay dividends?
There are several potential reasons why Swedish Orphan Biovitrum would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Swedish Orphan Biovitrum ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Swedish Orphan Biovitrum has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Swedish Orphan Biovitrum a dividend aristocrat?
Swedish Orphan Biovitrum is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Swedish Orphan Biovitrum a dividend king?
Swedish Orphan Biovitrum is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Swedish Orphan Biovitrum a dividend stock?
No, Swedish Orphan Biovitrum is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Swedish Orphan Biovitrum stocks?
To buy Swedish Orphan Biovitrum you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Swedish Orphan Biovitrum stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.